Ex Vivo Activated Haploidentical Natural Killer Cell Therapy

体外激活单倍体相合自然杀伤细胞疗法

Report date: 2022/12/31 17:30:31

Base Information

Drug NameEx Vivo Activated Haploidentical Natural Killer Cell Therapy
Drug Alias NameNK cell therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsNeuroblastomaGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIran
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesRoyan Institute
China Registration ClassN/A

Develop Information

Active CompaniesRoyan Institute
Inactive CompaniesN/A
Active IndicationsNeuroblastoma
Inactive IndicationsGlioblastoma

Other Information

ATC CodeN/A
Related LinksN/A